Top Page
WELL Health Technologies Corp
(TSX:WELL)
WELL Health Technologies Corp (WELL) vs. S&P 500 (SPY)
WELL Health Technologies Corp Business Overview & Revenue Model
WELL Health Technologies Corp Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 919.69M | 776.05M | 569.14M | 302.32M | 50.24M | Gross Profit |
| 363.01M | 372.27M | 303.29M | 153.69M | 21.22M | EBIT |
| -30.20M | 35.16M | 23.31M | -6.21M | -9.90M | EBITDA |
| 116.80M | 101.88M | 95.99M | 21.27M | -495.00K | Net Income Common Stockholders |
| 32.61M | 82.00K | 19.07M | -30.69M | -2.62M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 131.67M | 43.42M | 48.91M | 61.92M | 86.89M | Total Assets |
| 1.81B | 1.41B | 1.32B | 1.26B | 262.73M | Total Debt |
| 425.09M | 426.28M | 358.42M | 401.94M | 23.57M | Net Debt |
| 293.42M | 382.86M | 309.51M | 340.02M | -63.32M | Total Liabilities |
| 877.55M | 563.16M | 503.78M | 554.37M | 43.75M | Stockholders Equity |
| 867.61M | 767.67M | 732.34M | 618.24M | 217.37M |
| Cash Flow | Free Cash Flow | |||
| -6.70M | 37.20M | 70.14M | 19.59M | -6.52M | Operating Cash Flow |
| 9.52M | 66.44M | 76.55M | 22.27M | -5.38M | Investing Cash Flow |
| -60.23M | -106.42M | -37.93M | -499.78M | -44.21M | Financing Cash Flow |
| 133.50M | 10.63M | -52.85M | 452.53M | 120.84M |
WELL Health Technologies Corp Technical Analysis
WELL Health Technologies Corp Peers Comparison
WELL Health Technologies Corp Earnings Call Summary
WELL Health Technologies Corp Corporate Events
WELL Health Technologies Corp announced its financial results for Q4 and the full year 2024, reporting a record annual revenue of $919.7 million, a 19% increase from the previous year. Despite challenges such as deferred revenue from Circle Medical and impacts from a cyberattack on Change Healthcare, the company achieved significant growth in patient visits and Canadian operations. WELL Health projects a positive outlook for 2025, with expected revenue between $1.40 billion to $1.45 billion and Adjusted EBITDA ranging from $190 million to $210 million, driven by strong organic growth and strategic initiatives.
Spark’s Take on TSE:WELL Stock
According to Spark, TipRanks’ AI Analyst, TSE:WELL is a Outperform.
WELL Health Technologies Corp’s strong financial performance and positive earnings call are significant factors contributing to a high score. The company’s robust revenue growth, improved profitability, and strategic expansion plans are offset by mixed technical indicators and fair valuation.
To see Spark’s full report on TSE:WELL stock, click here.
WELL Health Technologies Corp. announced it will release its Fiscal Fourth Quarter and Year End 2024 financial results on April 14, 2025, after market close. The company will host a conference call and webcast on April 15, 2025, to discuss the results, led by CEO Hamed Shahbazi and CFO Eva Fong. This announcement reflects WELL’s ongoing commitment to transparency and engagement with stakeholders, as it continues to expand its influence in the digital healthcare sector.
Spark’s Take on TSE:WELL Stock
According to Spark, TipRanks’ AI Analyst, TSE:WELL is a Outperform.
WELL Health Technologies Corp’s strong financial performance and positive earnings call are significant factors contributing to a high score. The company’s robust revenue growth, improved profitability, and strategic expansion plans are offset by mixed technical indicators and fair valuation.
To see Spark’s full report on TSE:WELL stock, click here.
WELL Health Technologies Corp. announced that the British Columbia Securities Commission has granted a management cease trade order (MCTO) due to a delay in filing its annual information form and financial statements for the year ended December 31, 2024. The MCTO restricts the CEO and CFO from trading company securities until the filings are completed, though it does not affect non-insider shareholders. WELL is committed to completing the filings promptly and will provide bi-weekly updates as per regulatory guidelines. This development highlights the company’s ongoing efforts to address the delay and ensure compliance with financial reporting obligations.
WELL Health Technologies Corp. has exercised its call option to acquire a significant stake in HEALWELL AI Inc., following HEALWELL’s acquisition of Orion Health Holdings Limited. This move increases WELL’s economic interest to 37% and voting rights to 69% in HEALWELL, positioning WELL as a control person and potentially enhancing its influence and strategic direction in the healthcare technology sector.
WELL Health Technologies Corp has announced its intention to exercise a call option to acquire a significant number of shares in HEALWELL AI Inc. The exercise of this option is contingent upon the completion of HEALWELL’s acquisition of Orion Health Holdings Limited, valued at approximately NZ$175 million. This strategic move is expected to significantly increase WELL’s ownership and voting rights in HEALWELL, enhancing its influence and control over the company.
WELL Health Technologies Corp. reported record patient visits and Total Care Interactions for fiscal year 2024, with a 32% year-over-year growth in patient visits driven primarily by organic growth. The company’s Canadian patient services business led this expansion, with a 35% increase in patient visits. The results underscore WELL’s strong operational performance and its technology-enabled care model’s effectiveness in driving growth and improving patient outcomes. This growth reflects WELL’s strategic positioning in the digital healthcare industry and its commitment to empowering healthcare providers through innovative technology solutions.
WELL Health Technologies Corp. announced its intention to amend and exercise its call right to acquire a majority controlling interest in HEALWELL AI Inc., a healthcare artificial intelligence company, concurrent with HEALWELL’s proposed acquisition of Orion Health. This strategic move is expected to enhance WELL’s industry positioning by combining its scale with HEALWELL’s AI expertise and Orion’s global health information systems experience, potentially contributing approximately $160 million in revenue to WELL’s financial statements over the next year.
WELL Health Technologies Corp has announced a delay in filing its audited annual consolidated financial statements for the year ended December 31, 2024, due to accounting issues related to its US subsidiary, Circle Medical Technologies, Inc. The delay is linked to an investigation by the US Attorney’s Office into Circle Medical’s billing practices. Despite the delay, WELL Health does not anticipate a material impact on its cash position or resources and expects to file the necessary documents by April 15, 2025. The company is also exploring strategic alternatives for Circle Medical.
WELL Health Technologies Corp. has expanded its Canadian Clinics network by adding 11 clinics, generating $29 million in revenue and $2 million in EBITDA, demonstrating robust growth with a 24% organic increase in 2024. The company is capitalizing on a surge in ‘Buy Canadian’ sentiment, with a record pipeline of 70 public sector opportunities worth over $300 million, reflecting its strategic focus on expanding its technology services and strengthening its position in the Canadian healthcare sector.
WELL Health Technologies’ subsidiary, WELLSTAR, announced key additions to its management team and provided updates on recent acquisitions. Sarah Xu and Frank Seiferth joined as Vice Presidents, bringing significant experience in growth operations and product strategy. WELLSTAR also completed acquisitions of Microquest and Bluebird iT, expanding its technology solutions to over 40% of Canadian physicians. These strategic moves are expected to enhance WELLSTAR’s market presence, drive innovation, and support healthcare providers with digital and AI-enabled solutions, reinforcing its position as a leader in Canadian healthcare technology.
WELL Health Technologies Corp provided an update on the financial performance of its recently acquired Canadian clinics, showcasing strong profitability and growth with impressive return on invested capital (ROIC) figures. The company revealed a robust M&A pipeline, indicating significant expansion in the Canadian healthcare sector with plans to continue its growth trajectory. Despite potential U.S.-Canada tariff escalations, WELL remains resilient due to its lack of cross-border operations and significant revenue generation from U.S.-based entities.